Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial.

MLA

Simpson, Eric L., et al. “Dupilumab Treatment Improves Signs, Symptoms, Quality of Life, and Work Productivity in Patients with Atopic Hand and Foot Dermatitis: Results from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial.” Journal of the American Academy of Dermatology, vol. 90, no. 6, June 2024, pp. 1190–99. EBSCOhost, https://doi.org/10.1016/j.jaad.2023.12.066.

APA

Simpson, E. L., Silverberg, J. I., Worm, M., Honari, G., Masuda, K., Syguła, E., Schuttelaar, M. L. A., Mortensen, E., Laws, E., Akinlade, B., Patel, N., Maloney, J., Paleczny, H., Delevry, D., Xiao, J., Dubost-Brama, A., & Bansal, A. (2024). Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial. Journal of the American Academy of Dermatology, 90(6), 1190–1199. https://doi.org/10.1016/j.jaad.2023.12.066

Chicago

Simpson, Eric L., Jonathan I. Silverberg, Margitta Worm, Golara Honari, Koji Masuda, Ewa Syguła, Marie L.A. Schuttelaar, et al. 2024. “Dupilumab Treatment Improves Signs, Symptoms, Quality of Life, and Work Productivity in Patients with Atopic Hand and Foot Dermatitis: Results from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial.” Journal of the American Academy of Dermatology 90 (6): 1190–99. doi:10.1016/j.jaad.2023.12.066.